U.S. stocks stack up well vs. the rest of the world based on valuation, even as the price charts hint at the possibility of coming U.S. outperformance.
In most biotech life cycles, there are always several defining moments that could make or break their valuations
Investors poured $30 billion into taxable-bond funds and another $5.6 billion into municipal-bond funds in August.
Two important signals are saying that stocks are not overbought at these levels and the longer-term market trend is still to the upside.
The world still has a growing thirst for oil amid the continued worries of an economic slowdown. That may benefit some oil and gas MLPs.
As we head into the fall, our models indicate the currently lower volatility will likely stay for a period of time.
I believe we are nearing the point where the tech sector will rise again as it did in the late nineties.
As the portfolio is full of powerful companies, there are always things happening which are eventful.
The portfolio might better be called the Stock Market Darwinism model as I seek only top dogs for inclusion.